Welcome to our dedicated page for Astellas Pharma news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma stock.
Astellas Pharma Inc. news covers developments from a Japanese pharmaceutical company and its unsponsored ADR, including oncology data, licensing activity, research collaborations and patient-focused programs. Recurring updates include clinical presentations for approved cancer therapies such as XTANDI with Pfizer, oncology pipeline additions such as the clinical-stage antibody-drug conjugate XNW27011, and collaborations that support drug-discovery startups in Japan, Korea and U.S. life-science incubators.
Company announcements also address patient advocacy initiatives, research-center and incubator access through programs such as SakuLab™-Tsukuba, and business-development agreements that expand Astellas' therapeutic and technology capabilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Astellas Pharma announced the publication of results from the Phase 3 SPOTLIGHT trial evaluating zolbetuximab in combination with mFOLFOX6 for patients with CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma. Published in The Lancet, the trial met its primary endpoint of progression-free survival (PFS) and secondary endpoint of overall survival (OS). Key findings include a 24.9% reduced risk of progression or death and a median PFS of 10.61 months for zolbetuximab versus 8.67 months for placebo. OS data revealed a 25% reduced risk of death, with median OS of 18.23 months for the treatment group. The SPOTLIGHT study establishes the clinical benefit of zolbetuximab, supporting Astellas' development efforts in gastric cancer.
On April 11, 2023, Kyoto University's Center for iPS Cell Research and Application (CiRA) and Astellas Pharma entered the second phase of their joint research agreement. This phase focuses on enhancing the use of differentiated cells from human induced pluripotent stem cells (iPS cells) for innovative medical solutions. Building on prior research from July 2017 to March 2023, the collaboration will establish a technological platform to produce high-quality iPS cell-derived cells. The key initiatives include developing evaluation systems to improve clinical predictability and creating new cell therapy programs. CiRA's Director, Jun Takahashi, and Astellas' CSO, Yoshitsugu Shitaka, express optimism about the potential advancements in drug discovery and treatment options for various diseases.